SCHEMBL24420552

SCHEMBL24420552

CCCc1c(F)[nH]c2ccc(F)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.48
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
KIF11 P52732 1/20 0.44
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
MPO P05164 8/20 0.43
GABRA1 P14867 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43
TSHR P16473 2/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 2/20 0.41
HTT P42858 2/20 0.41
GALR3 O60755 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4815613 0.85 MEN1 (0.61) GHSRMEN1KMT2AKIF11KEAP1
SCHEMBL22417993 0.81 MEN1 (0.54) GHSRMEN1KMT2AKIF11KEAP1
SCHEMBL14499883 0.80 GHSR (0.43) GHSRMEN1KMT2AKIF11KEAP1
SCHEMBL7121392 0.75 KDM4E (0.65) GHSRMEN1KMT2AKEAP1NFE2L2
SCHEMBL15886438 0.75 KIF11 (0.46) GHSRKIF11KEAP1NFE2L2MPO
SCHEMBL19192790 0.74 SMN1; SMN2 (0.53) GHSRMEN1KMT2AKIF11KEAP1
SCHEMBL24420290 0.71 MEN1 (0.44) MEN1KMT2AKIF11KDM4ELMNA
SCHEMBL28750582 0.70 TSPO (0.56) HSD17B10KDM4ESMN1; SMN2HTR2AALDH1A1
SCHEMBL8244089 0.70 HTR6 (0.68) MEN1KMT2AKIF11KEAP1NFE2L2
SCHEMBL21746319 0.70 KIF11 (0.41) GHSRKIF11KEAP1NFE2L2MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220143051-A1 COMPOSITIONS AND METHODS OF USE COMPRISING SUBSTANCES WITH NEURAL PLASTICITY ACTIONS ADMINISTERED AT NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSAGES AND FORMULATIONS Arbormentis LLC (US) 2022-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143051-A1 COMPOSITIONS AND METHODS OF USE COMPRISING SUBSTANCES WITH NEURAL PLASTICITY ACTIONS ADMINISTERED AT NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSAGES AND FORMULATIONS HTR2A, GRIN2A, HTR1A GHSR 443/4885MEN1 2814/4885KMT2A 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.